** Shares of Argent BioPharma RGT.AX rise as much as 52.9% to A$0.260, their biggest intraday pct gain since Oct 1, 2024
** The clinical-stage biopharma co completes $4.5 mln capital raise at $0.40 per share
** Issue price represents a premium of 276.5%, compared with stock's last closing price of A$0.17
** Says placement will help advance co's drug development pipeline, with focus on clinical studies for CannEpil - a seizure-control treatment for refractory epilepsy and cerebral palsy
** Stock hits its highest level since Dec 2
** About 231,485 shares change hands, 13.2 times the 30-day average volume of 17,562
** Stock fell 64.2% in 2024
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@ThomsonReuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。